Effect of Lactobacillus Rhamnosus on Serum Uremic Toxins in Hemodialysis
Not Applicable
Completed
- Conditions
- Hemodialysis Complication
- Interventions
- Dietary Supplement: Lactobacillus rhamnosusDrug: Placebo - Cap
- Registration Number
- NCT03527680
- Lead Sponsor
- nooshin dalili
- Brief Summary
Uremic toxins such as p-cresol and phenol are suggested to be associated with higher mortality in hemodialysis patients. The aim of this study was to investigate the effects of probiotics on serum p-cresol level in hemodialysis patients.
- Detailed Description
Overall, 42 hemodialysis patients (10 women and 32 men) were divided randomly into the Lactobacillus rhamnosus group (21 patients) and the placebo group (21 patients).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
• Age more than 20 years
- Acceptable performance of alimentary system
- Ability to drink at least 200 ml of water per day
- No history of being allergic to fungi and yeast
- Absence of acute medical illness
- life expectancy more than 3 months
- Accept and sign the consent
Exclusion Criteria
- Patient's unwillingness to participate in the study
- History of smoking, peritoneal dialysis (PD) or previous kidney transplantation
- Lactation or pregnancy
- Drug history including antibiotics, prebiotics, probiotics, herbal drugs, psychedelic drugs, flavors.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Lactobacillus rhamnosus Lactobacillus rhamnosus received daily one capsule containing 1.6\*107 CFU of Lactobacillus Rhamnosus Placebo Placebo - Cap received one placebo capsule per day Infant formula after meal for 28 days
- Primary Outcome Measures
Name Time Method pre- and post-treatment p-cresol levels 4 weeks
- Secondary Outcome Measures
Name Time Method